PHARMAC performance 2015/16 Q3
Performance data to 31 March 2015/16
Output Class 1: Decision-making
Measure: All funding decisions are supported by evidence and made using PHARMAC’s decision-making approach.
Status: On track. All funding decisions supported by evidence and made using PHARMAC’s decision-making approach.
Measure: Decisions on more than 90% of line items (excluding bids held open while awaiting Medsafe registration) will be made within six months of the tender closing.
Status: On track. The tender was released in November and closed 31 December 2015.
Measure: Cumulative five year value to Vote Health at 30 June 2016 exceeds cumulative five year value of additional baseline contribution to PHARMAC’s operation.
Status: On track. Five year cumulative value of all decisions since 2013/14 is $131.050 m compared to the additional baseline contribution of $6.208m in 2015/16
Output Class 2: Influencing medicines use
Measure: At least half of all DHBs or agents will engage with PHARMAC on implementing hospital medical device national contracts.
All relevant DHB hospital services will engage with PHARMAC to support hospital medicine changes.
Status: On Track. 16 out of 20 DHBs attended a second implementation workshop in April at PHARMAC to discuss implementation issues around moving to market share.
Measure: Surveys of attendees show at least 90% rate their satisfaction with the Seminars at least four out of five.
Status: On track. PHARMAC hosted 3 seminars in the period 1 January to 3o April 2016. 95% of respondents rated the seminars at least four out of five.
Measure: Community-based delivery of programme occurs in half of all MoA partner areas.
Status: On track. We currently have agreements with five Whānau Ora Collectives.
Measure: Respond to low medicine stock reports, communicate effectively and take action as necessary to ensure patient needs for medicines are met.
Status: On track. All stock reports are monitored and managed.
Output Class 3: Providing policy advice and support
Measure: An average survey score of at least 4.5 in each area.
Status: This survey is completed annually at year-end and reported in the final quarter report.
Measure: All fund use is in accordance with PHARMAC policy.
Status: On track. Policy is adhered to.
Last updated: 6 May 2016